Journal article
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer
E Domingo, DN Church, O Sieber, R Ramamoorthy, Y Yanagisawa, E Johnstone, B Davidson, DJ Kerr, IPM Tomlinson, R Midgley
Journal of Clinical Oncology | Published : 2013
Abstract
Purpose Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC) and are associated with reduced disease recurrence and improved outcome after primary treatment. However, toxicities of NSAIDs have limited their use as antineoplastic therapy. Recent data have suggested that the benefit of aspirin after CRC diagnosis is limited to patients with PIK3CA-mutant cancers. We sought to determine the predictive utility of PIK3CA mutation for benefit from both cyclooxygenase-2 inhibition and aspirin. Methods We performed molecular analysis of tumors from 896 participants in the Vioxx in Colorectal Cancer Therapy: Definition of Optimal Regime (VICTOR) tria..
View full abstractGrants
Awarded by European Commission
Funding Acknowledgements
The Vioxx in Colorectal Cancer Therapy: Definition of Optimal Regime (VICTOR) trial was supported by the University of Oxford and an educational study grant from Merck (Whitehouse Station, NJ). Molecular analyses were funded by grants from Cancer Research UK (Grant No. C6199/A10417), the European Union Seventh Framework Programme (Grant No. FP7/207-2013), Systems Biology of Colorectal Cancer collaborative project (Grant No. 258236), and the Oxford National Institute for Health Research Comprehensive Biomedical Research Centre. The Wellcome Trust Centre for Human Genetics receives core funding from the Wellcome Trust (090532/Z/09/Z). D.N.C. has received funding from the Oxford Cancer Research Centre.